Abstract:Aiming to explore novel BRAFV600E and VEGFR-2 dual inhibitors, a series of 1H-pyrazolo[3,4-d]pyrimidine derivatives were designed, synthesized and biologically evaluated in this study. Most of the synthesized 1H-pyrazolo[3,4-d]pyrimidine compounds displayed moderate to high potent activity in both enzymatic and cellular proliferation assays. Among these compounds, 9e, 9g, 9m and 9u showed remarkably high inhibitory activities against both BRAFV600E and VEGFR-2 kinase comparable to positive control Sorafenib. Particularly, compound 9u also showed potent anti-proliferative activity against BRAFV600E-expressing A375 (IC50 = 1.74 μM) and H-29 (IC50 = 6.92 μM) as well as VEGFR-2-expressing HUVEC (IC50 = 5.89 μM), which was also comparable to Sorafenib. Furthermore, kinase selectivity profile showed that 9u had almost poor or no significant inhibitory activity against wild-type BRAF and 15 other tested protein kinases. Flow cytometric analysis showed that compound 9u mainly arrested the A375 and HUVEC cell lines in the G0/G1 stage with a concentration-dependent effect. In addition, the molecular docking and molecular dynamics simulations suggested that 9u adopted a similar binding pattern with Sorafenib at the ATP-binding sites of BRAFV600E and VEGFR-2. Taken together, these results indicated that compound 9u may serve as novel lead compound in research on more effective BRAFV600E and VEGFR-2 dual inhibitors.

Discovery of Biphenyl-Aryl Ureas As Novel VEGFR-2 Inhibitors. Part 4: Exploration of Diverse Hinge-Binding Fragments

Discovery of Novel VEGFR-2 Inhibitors. Part 5: Exploration of Diverse Hinge-Binding Fragments Via Core-Refining Approach

Biphenyl Derivatives Incorporating Urea Unit As Novel Vegfr-2 Inhibitors: Design, Synthesis and Biological Evaluation

Discovery of novel VEGFR-2 inhibitors. Part II: Biphenyl urea incorporated with salicylaldoxime

Discovery of biphenyl-based VEGFR-2 inhibitors. Part 3: design, synthesis and 3D-QSAR studies.

Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors

Discovery of 4,6‐disubstituted Pyrimidine Derivatives As Novel Dual VEGFR2/FGFR1 Inhibitors

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Pyrimidinylacetamide-based 2-Pyridylureas As Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents

Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors

Discovery of 1,3‐diaryl‐pyridones As Potent VEGFR‐2 Inhibitors: Design, Synthesis, and Biological Evaluation

Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives As Angiogenesis Inhibitors: Design, Synthesis and in Vitro Biological Evaluation.

Discovery of Novel Anti-Angiogenesis Agents. Part 7: Multitarget Inhibitors of VEGFR-2, TIE-2 and EphB4.

Synthesis and Structure-Activity Relationships of Pyrazine-Pyridine Biheteroaryls As Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors.

Biological Evaluation of 4-Aryl-1,4-dihydropyridines As VEGFR-2 Kinase Inhibitors

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazo-line and diarylamide fragments

Design, Synthesis, Biological Evaluation of Benzoyl Amide Derivatives Containing Nitrogen Heterocyclic Ring As Potential VEGFR-2 Inhibitors

Design, Synthesis and Biological Evaluation of Pyrimidine-Based Derivatives As VEGFR-2 Tyrosine Kinase Inhibitors.

Discovery of Novel Picolinamide-Based Derivatives As Novel VEGFR-2 Kinase Inhibitors: Synthesis,in Vitrobiological Evaluation and Molecular Docking